WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014204014) HBV-SPECIFIC ARTIFICIAL DNA NUCLEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/204014    International Application No.:    PCT/JP2014/067092
Publication Date: 24.12.2014 International Filing Date: 20.06.2014
IPC:
C12N 15/09 (2006.01), A61K 31/711 (2006.01), A61K 38/46 (2006.01), A61K 48/00 (2006.01), A61P 31/20 (2006.01), C07K 19/00 (2006.01), C12N 9/16 (2006.01)
Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE [JP/JP]; 1-6, Kamikitazawa 2-chome, Setagaya-ku, Tokyo 1568506 (JP).
PHOENIXBIO CO., LTD. [JP/JP]; 4-1, Kagamiyama 3-chome, Higashihiroshima-shi, Hiroshima 7390046 (JP)
Inventors: KOHARA, Michinori; (JP).
ISHIDA, Yuji; (JP).
MUKAIDANI, Chise; (JP).
SHIMADA, Takashi; (JP)
Agent: HIRAKI, Yusuke; (JP)
Priority Data:
2013-130908 21.06.2013 JP
Title (EN) HBV-SPECIFIC ARTIFICIAL DNA NUCLEASE
(FR) DÉSOXYRIBONUCLÉASE ARTIFICIELLE SPÉCIFIQUE DU VHB
(JA) HBV特異的人工DNAヌクレアーゼ
Abstract: front page image
(EN)The purpose of the present invention is to provide a novel therapeutic means for curing HBV infections. Provided is an HBV-specific artificial DNA nuclease comprising: a transcription activator-like effector (TALE) derived from Xanthomonas bacterium modified so as to specifically bond with HBV DNA; and a sequence-independent endonuclease.
(FR)L'invention a pour objectif de fournir un nouveau moyen thérapeutique permettant de soigner une infection par le VHB. L'invention concerne une désoxyribonucléase artificielle spécifique du VHB comprenant : un effecteur du type activateur de transcription (TALE) dérivé de la bactérie Xanthomonas modifiée pour se lier de manière spécifique à l'ADN du VHB; et une endonucléase indépendante des séquences.
(JA)HBV感染の根治を目的とする新たな治療手段を提供することを目的とする。 HBV DNAと特異的に結合するように改変されたXanthomonas属細菌由来のTALEと、配列非依存性のエンドヌクレアーゼとを含んでなる、HBV特異的人工DNAヌクレアーゼ。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)